CDX-1140 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: CD40 monoclonal antibody

Filter by location:

Chicago, Illinois1 trial

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

University of Chicago Comprehensive Cancer Center

Phase 1

Bethesda, Maryland1 trial

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

National Institutes of Health Clinical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.